Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

3.695 -0.015 (-0.40%)

Delayed Quote Updated: 3:09 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences

November 01, 2022

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Why Super Micro Computer Shares Jumped Over 10%; Here Are 73 Biggest Movers From Yesterday ↗

October 21, 2022

Gainers NextPlay Technologies, Inc. (NASDAQ: NXTP) shares climbed 107.3% to close at $0.4138 on Thursday after the company announced its NextFintech division received commitment for a $15 million...

Via Benzinga

Recap: Fulcrum Therapeutics Q2 Earnings ↗

August 11, 2022

Fulcrum Therapeutics (NASDAQ:FULC) reported its Q2 earnings results on Thursday, August 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Why Ericsson Shares Are Trading Lower? Here Are 56 Stocks Moving In Thursday's Mid-Day Session ↗

October 20, 2022

Gainers NextPlay Technologies, Inc. (NASDAQ: NXTP) shares jumped 126% to $0.4525 after the company announced its NextFintech division received commitment for a $15 million strategic investment.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 19, 2022

Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million.

Via Benzinga

4 Analysts Have This to Say About Fulcrum Therapeutics ↗

June 13, 2022

Within the last quarter, Fulcrum Therapeutics (NASDAQ:FULC) has observed the following analyst ratings:

Via Benzinga

Analyst Ratings for Fulcrum Therapeutics ↗

May 17, 2022

Within the last quarter, Fulcrum Therapeutics (NASDAQ:FULC) has observed the following analyst ratings:

Via Benzinga

Recap: Fulcrum Therapeutics Q1 Earnings ↗

May 09, 2022

Fulcrum Therapeutics (NASDAQ:FULC) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada

October 12, 2022

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 07, 2022

From Fulcrum Therapeutics, Inc.

Via GlobeNewswire

U.S. Stock Futures Edge Lower Ahead Of Walmart, Home Depot Earnings ↗

August 16, 2022

Pre-open movers

Via Benzinga

Walmart, Home Depot And 3 Stocks To Watch Heading Into Tuesday ↗

August 16, 2022

With US stock futures trading slightly lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Fulcrum Therapeutics Earnings Preview ↗

August 10, 2022

Fulcrum Therapeutics (NASDAQ:FULC) is set to give its latest quarterly earnings report on Thursday, 2022-08-11. Here's what investors need to know before the announcement.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 12, 2022

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 11, 2022

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

June 13, 2022

RBC Capital reduced Tesla, Inc. (NASDAQ: TSLA) price target from $1,175 to $1,100. Tesla shares fell 3.7% to $670.89 in pre-market trading.

Via Benzinga

Mid-Afternoon Market Update: Dow Drops Over 600 Points; Fulcrum Therapeutics Shares Tumble ↗

June 10, 2022

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 600 points on Friday.

Via Benzinga

91 Biggest Movers From Friday ↗

June 13, 2022

Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 10, 2022

Via Benzinga

Mid-Day Market Update: Nasdaq Dips 400 Points; Cogent Biosciences Shares Jump ↗

June 10, 2022

U.S. stocks traded lower midway through trading, with the Nasdaq Composite tumbling around 400 points on Friday.

Via Benzinga

44 Stocks Moving In Friday's Mid-Day Session ↗

June 10, 2022

Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial.

Via Benzinga

Mid-Morning Market Update: Markets Open Lower; US Inflation Rate Accelerates to 8.6% ↗

June 10, 2022

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 600 points on Friday.

Via Benzinga

Looking Into Fulcrum Therapeutics's Return On Capital Employed ↗

June 03, 2022

Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q1 sales of $2.59 million. Earnings fell to a loss of $25.93 million, resulting in a 10.41% decrease from last quarter.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

June 01, 2022

On Wednesday, 73 stocks hit new 52-week lows.

Via Benzinga

Earnings Preview: Fulcrum Therapeutics ↗

May 06, 2022

Fulcrum Therapeutics (NASDAQ:FULC) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Fulcrum...

Via Benzinga

Fulcrum Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

May 04, 2022

Fulcrum Therapeutics (NASDAQ:FULC) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 13, 2022

Gainers

Via Benzinga

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗

April 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

Fulcrum Therapeutics's Return On Capital Employed Overview ↗

March 09, 2022

Benzinga Pro data, Fulcrum Therapeutics (NASDAQ:FULC) reported Q4 sales of $5.06 million. Earnings fell to a loss of $23.48 million, resulting in a 13.36% decrease from last...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.